Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional Essentials · Free · No registration

Psoriatic arthritis: recognize the domains, treat the person

A clinical framework for diagnosis, treatment selection, axial disease and meaningful follow-up.

Clinically reviewed: October 4, 2026 · Free to read · English

Psoriatic arthritis (PsA) can combine joint, entheseal, digital, spinal, skin and nail disease in the same person. Its clinical challenge is deciding which manifestations are active, which symptoms have another explanation, and which treatment can address the relevant combination. Neither skin clearance nor a normal inflammatory marker settles the musculoskeletal assessment. Early recognition must lead to a documented treatment target and an achievable review plan.

1. Establish inflammation before applying a label

Look for synovitis, whole-digit swelling, entheseal involvement and axial symptoms. Examine feet and distal interphalangeal joints; inspect nails and less visible psoriasis sites, and ask about personal and family history. GRAPPA organizes care around six domains: peripheral arthritis, axial disease, enthesitis, dactylitis, skin and nails. Record the actual phenotype rather than relying on a single joint pattern.

CASPAR classification starts with established inflammatory articular disease and then applies characteristic features. Psoriasis plus negative rheumatoid factor cannot establish that prerequisite. Psoriasis may coexist with rheumatoid arthritis, osteoarthritis or crystal disease. A new hot swollen joint requires its own urgent infection assessment; an established PsA diagnosis is not an explanation for every subsequent episode.

Tenderness alone does not prove inflammatory enthesitis. If attribution remains uncertain, ask a focused imaging question and interpret the finding with loading history, examination and competing pain mechanisms. Structural abnormalities and current inflammation are different observations.

Suspected septic arthritis requires prompt synovial sampling for culture, cell count and crystals; crystals do not exclude infection. Obtain cultures before antibiotics when feasible, but do not delay treatment of sepsis. The SANJO guideline provides the acute pathway. A painful photophobic red eye or visual change likewise needs urgent ophthalmic assessment, separate from routine arthritis review.

CASPAR and difficult diagnostic boundaries → Professional access required

2. Measure activity, damage and impact separately

Document swollen and tender joints, active domains, function and the patient’s principal limitation. Radiographic damage may explain disability without proving ongoing inflammation. Conversely, inflammation can be clinically important before radiographs show erosions. Normal CRP is common in active PsA and must not override convincing findings.

DAPSA provides a reproducible peripheral-joint assessment using full joint counts, pain, patient global assessment and CRP; cDAPSA omits CRP. Neither establishes control of every domain. Minimal disease activity requires five of seven criteria, so residual activity can remain despite meeting the composite. Record failed criteria and clinically important sites instead of reporting only “target achieved.”

A large numerical improvement is not necessarily remission. Compare the same measure over time, preserve units and components, and pair the score with a concrete functional goal such as walking to work or using the hands for dressing.

Monitoring and discordant findings → Professional access required

3. Start effective treatment and reassess it

Exercise, rehabilitation and appropriate symptom relief support care, but persistent inflammatory arthritis needs a disease-modifying strategy. The EULAR 2023 update recommends prompt conventional DMARD treatment for polyarthritis or oligoarthritis with poor prognostic factors, favoring methotrexate when skin disease is relevant; inadequate response to a conventional DMARD supports a biologic. The ACR/NPF guideline conditionally favors a TNF inhibitor over an oral small molecule in treatment-naive active PsA. These are different recommendation frameworks, not a universal mandatory sequence.

Agree what improvement would justify continuation, when it should occur and what would trigger a change. The randomized TICOPA strategy trial supports active reassessment and escalation toward a target, while also showing more adverse events with tight control. It supports a treatment strategy, not identical visit intervals for everyone.

Before declaring failure, confirm dose, duration, adherence, tolerability and actual access. Persistent inflammation despite adequate exposure differs from an interrupted prescription or pain driven by damage. Each requires a different next step.

The dominant domain matters: a conventional DMARD chosen for peripheral synovitis is not automatically the answer to persistent enthesitis or axial disease. Explain which manifestation the proposed drug should control and which residual problems need another intervention. Local injections may help selected sites after infection is excluded; repeated symptom relief should not conceal an inadequate long-term strategy.

Choosing and changing therapy → Professional access required

4. Assess axial disease on its own evidence

Persistent back or neck symptoms require clinical attribution even when skin and peripheral joints are controlled. Consider degenerative disease and other causes; neither negative HLA-B27 nor a normal CRP excludes axial involvement. Imaging must address the symptomatic region and distinguish inflammatory from structural and mechanical changes.

Conventional DMARDs are not an established axial treatment. EULAR includes TNF, IL-17 and JAK inhibition for clinically relevant axial disease after inadequate NSAID response, with individual safety assessment. MAXIMISE provides direct randomized evidence for secukinumab in a selected axial PsA population; it does not rank all available mechanisms.

Evidence is evolving: the September 25, 2026 STAR sponsor announcement reported favorable guselkumab axial and MRI outcomes. Detailed results were still forthcoming in that announcement. This is emerging evidence, not a completed comparative treatment hierarchy.

Axial PsA: treatment evidence and its limits → Professional access required

5. Let associated disease and safety shape selection

Uveitis or inflammatory bowel disease can change the preferred agent. An appropriate monoclonal TNF inhibitor can address these conditions; etanercept is not interchangeable. Avoid IL-17 inhibition in active IBD and coordinate treatment with gastroenterology. Prominent skin disease also influences mechanism choice.

FDA warnings for selected JAK inhibitors address serious cardiovascular events, malignancy, thrombosis and mortality. Apply agent-specific indications and assess individual risk rather than treating oral therapy as inherently safer. The June 2026 US deucravacitinib label includes active adult PsA; it is no longer investigational for that indication. TYK2 selectivity does not establish risk-free treatment, and the label states that applicability of JAK-associated risks is unknown.

Before advanced therapy, address TB and hepatitis screening, infection history and organ function. Review vaccination and assign responsibility for drug-specific laboratory monitoring. Fever or systemic illness deserves prompt assessment rather than automatic attribution to a flare.

Associated conditions and prevention → Professional access required

6. Preserve control through changing circumstances

At follow-up, reassess all previously active domains and the patient’s priorities. Address cardiovascular risk, smoking, metabolic health, sleep, mood and persistent pain alongside inflammatory treatment. High symptom burden with little demonstrable inflammation calls for investigation and support, not dismissal or automatic immunosuppressive escalation.

When considering another targeted agent, distinguish primary nonresponse, later loss of benefit, intolerance and a new domain mismatch. Record the reason for switching and the outcome that will determine whether the change succeeded.

Discuss reproductive plans before an urgent medication change is needed. EULAR’s 2024 reproductive update, published in 2025, supports compatible disease control through pregnancy and breastfeeding, including TNF inhibitors after individual assessment. This does not extend to every small molecule. Pregnancy and perioperative plans must name the drug, dates, replacement strategy and responsible team. End each visit with a review date and clear reasons to seek earlier assessment.

Pregnancy, breastfeeding and surgery → Professional access required

Sources and clinical review

Clinically reviewed October 4, 2026, against the professional collection and the primary studies, official recommendations and prescribing information below.

  1. Coates et al. GRAPPA updated treatment recommendations 2021. Nat Rev Rheumatol. 2022.
  2. Taylor et al. Development of CASPAR classification criteria. Arthritis Rheum. 2006.
  3. Ravn et al. Guideline for management of septic arthritis in native joints (SANJO). J Bone Jt Infect. 2023.
  4. Gialouri et al. Normal CRP in active PsA. Ther Adv Musculoskelet Dis. 2022.
  5. Schoels et al. DAPSA disease states and treatment response. Ann Rheum Dis. 2016.
  6. Coates et al. Defining minimal disease activity in PsA. Ann Rheum Dis. 2010.
  7. Gossec et al. EULAR PsA management: 2023 update. Ann Rheum Dis. 2024.
  8. Singh et al. 2018 ACR/NPF treatment guideline. Arthritis Care Res. 2019.
  9. Coates et al. TICOPA randomized strategy trial. Lancet. 2015.
  10. Baraliakos et al. MAXIMISE randomized trial. Ann Rheum Dis. 2021.
  11. Johnson & Johnson. STAR topline results. Sponsor announcement, September 25, 2026; not a full trial publication.
  12. FDA. Safety warnings for selected JAK inhibitors.
  13. SOTYKTU US prescribing information. Revised June 2026.
  14. Fragoulis et al. EULAR infection screening and prophylaxis recommendations. 2022 recommendations, published 2023.
  15. Bass et al. 2022 ACR vaccination guideline. Published 2023.
  16. Rüegg et al. EULAR reproduction recommendations: 2024 update. Ann Rheum Dis. 2025.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Rheumatology